PD-1, LAG-3 and TIM-3 Checkpoint Blockade in DLBCL Post Chimeric Antigen Receptor T-cEll Therapy fAilUre (PLATEAU Study) is a PHASE1 clinical asset sponsored by University of Alabama at Birmingham in Diffuse Large B Cell Lymphoma, Lymphoma, B-Cell, Lymphoma, Follicular. SEO and diligence focus: Retifanlimab, INCAGN02385, INCAGN02390, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.